We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Covis Pharma

News List

AstraZeneca to sell drug rights to Covis Pharma in $371m deal pharmaceutical-technology
November 10, 2018
AstraZeneca has agreed to divest its rights for Alvesco (ciclesonide), Omnaris and Zetonna (ciclesonide) medicines to Swiss speciality pharmaceutical firm Covis Pharma in a deal valued up to $371m.
Deals this week: AstraZeneca, Yuhan, Bristol-Myers americanpharmaceuticalreviewpharmaceutical-technol
November 10, 2018
Covis Pharma currently markets the drugs in the US. The divestment will enable AstraZeneca to focus on the development of new and innovative drugs to fulfil the unmet needs of patients.
AstraZeneca Sells Rights to Alvesco, Omnaris and Zetonna to Covis Pharma americanpharmaceuticalreview
November 10, 2018
AstraZeneca has entered into an agreement with Covis Pharma to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated